|
⚲
|
| Keyboard |
| DAFNA Capital Management LLC
✚
|
|
|---|---|
| CRD # | 129053 |
| SEC # | 801-62559 |
| CIK # | 0001389933 |
| AUM | 645.2 M (2026-03-30) |
| Employees | 8 (88% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 310-954-3200 |
| Address | 10990 Wilshire Boulevard Los Angeles, CA 90024 |
| Source | [IAPD] [EDGAR] [Website] [Twitter] [LinkedIn] |
| Total AUM ($M) |
|---|
| Fees and Compensation — Form ADV Part 2A (3/30/2026) [Brochure] |
|---|
5. Fees and Compensation Private Investment Funds A. Types of Fees Under Adviser’s investment management agreement with each Fund, Adviser will receive an annual management fee based on the account balance of each Fund investor. Adviser, in its discretion, may waive or reduce the management fee as to all or any of the investors in the Fund or agree with an investor to waive or alter the management fee as to that investor. Under Adviser’s investment management agreement with each Fund or the Fund’s charter documents, as applicable, Adviser will also receive an annual performance-based fee or allocation in arrears based on the net capital appreciation (i.e., capital appreciation less capital depreciation) of each investor’s account in the Fund. The performance-based fee or allocation is payable only if, and to the extent that, the net capital appreciation of the investor’s account exceeds any net capital depreciation accumulated in prior years (as adjusted for withdrawals of capital). Adviser, in its discretion, may waive or reduce the performance-based fee or allocation as to all or any of the investors in the Fund or agree with an investor to waive or alter the performance-based fee or allocation as to that investor. B. Payment Method The management fee will be paid by each Fund monthly in arrears by deduction from each investor’s account in the Fund on the last business day of the calendar month. The performance-based fee or allocation is also paid by deduction from each investor’s account in the Fund on December 31 of each year in which a performance-based fee or allocation is earned. If an investor withdraws all or a portion of its account in a Fund on a date other than December 31, a performance-based fee or allocation will be made on the amount withdrawn for the period from the prior January 1 to the date of withdrawal. C. Costs and Expenses Each Fund bears all expenses of its organization and operations, expenses incurred in the purchase and sale of investments, and accounting fees, as determined by Adviser. Such expenses include but are not limited to: (i) brokerage and execution charges, commissions, custodial charges, and fees for quotation and other data services; (ii) fees related to accounting, trading, portfolio management and risk management systems; (iii) research subscriptions and expenses; (iv) broken trade and broken deal fees; (v) expenses to register securities and transfer taxes; (vi) costs and expenses incurred for the purpose of protecting and enhancing the value of the Fund’s investments (including the costs of instituting and defending litigation); (vii) taxes, filing and registration fees of the Fund; (viii) all costs, fees and expenses relating to investor communications, relations, accounting and the preparation and mailing of financial, tax and performance information to investors, including an allocable share of the Adviser’s costs, fees and expenses relating to internal accounting and tax preparation function; (ix) fees, costs and expenses incurred in connection with borrowings; (x) Fund administration fees, costs and expenses; and (xi) fees for attorneys, accountants, consultants and other professionals or experts including legal and consulting fees related to investment research; (xi) premiums and other costs of D&O/E&O and other insurance and (xii) Form ADV Brochure – Part 2A DAFNA Capital Management LLC SEC #: 801-62559 all regulatory and compliance fees, costs, and expenses incurred in complying with regulatory requirements that directly result from management of the Fund (including expenses incurred in complying with FATCA and preparing Form PF). For additional information regarding brokerage and execution fees, see Item 12 below. D. Refunds. Not applicable. E. Sales Compensation. Adviser will not receive sales commissions in connection with sales of interests in a Fund. Form ADV Brochure – Part 2A DAFNA Capital Management LLC SEC #: 801-62559 |
| Account Minimums and Types of Clients — Form ADV Part 2A (3/30/2026) [Brochure] |
|---|
7. Types of Clients Private Investment Funds Adviser is organized and serves as general partner and/or discretionary investment adviser to several private investment funds, including DAFNA Fund, L.P., a Delaware limited partnership (the “Onshore Fund”), DAFNA International Fund, Ltd., a Cayman Islands exempted company (the “Offshore Fund”), DAFNA LifeScience, L.P., a Delaware limited partnership and DAFNA LifeScience Select, L.P., a Delaware limited partnership (the “Master Funds”). Adviser may decide in the future to sponsor or manage additional private investment funds. Adviser generally requires investors in a Fund to make a minimum initial investment of at least $1,000,000 and to maintain a minimum account balance of $1,000,000 in the Fund. Investors generally must be “accredited investors” under Regulation D who are also “qualified purchasers” under Section 2(a)(51)(A) of the Investment Company Act of 1940, as amended. Adviser generally requires Fund investors to make representations concerning their financial sophistication and ability to bear the risk of loss of their entire investment in the Fund. The minimum contribution and investor requirements may be waived by Adviser in its sole discretion. Form ADV Brochure – Part 2A DAFNA Capital Management LLC SEC #: 801-62559 |
| Sector | Form 13F Holdings | Value ($M) | |
|---|---|---|---|
| Revolution Medicines Inc | 56.5 | ||
| Stereotaxis Inc | 25.2 | ||
| AtriCure Inc | 17.0 | ||
| IDEAYA Biosciences Inc | 15.9 | ||
| Xenon Pharmaceuticals Inc | 14.6 | ||
| Cytokinetics Inc | 14.3 | ||
| Compass Pathways PLC | 13.4 | ||
| Nektar Therapeutics | 11.9 | ||
| Arcus Biosciences Inc | 9.6 | ||
| Neurocrine Biosciences Inc | 9.3 | ||
| View All | |||
| Holdings by Sector ($M) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| HF | DAFNA Fund LP Series A | [2012-03-29] | 401.7 M | 262.3 M |
| Filed 2026-03-30 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $1,000,000 · Remaining Indefinite · Duration More than one year · Net Assets Over $100,000,000 | ||||
| HF | DAFNA Fund LP Series B | [2012-03-29] | 401.7 M | 0.5 M |
| Filed 2026-03-30 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $1,000,000 · Remaining Indefinite · Duration More than one year · Net Assets Over $100,000,000 | ||||
| HF | DAFNA Fund LP Series C | [2012-03-29] | 401.7 M | 169.8 M |
| Filed 2026-03-30 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $1,000,000 · Remaining Indefinite · Duration More than one year · Net Assets Over $100,000,000 | ||||
| HF | DAFNA International Fund Ltd Class A | 2012-03-29 | 160.5 M | |
| HF | DAFNA International Fund Ltd Class B | 2012-03-29 | ||
| HF | DAFNA International Fund Ltd Class C | 2012-03-29 | 43.6 M | |
| HF | DAFNA Lifescience LP | 2012-03-29 | 431.7 M | |
| HF | DAFNA Lifescience Market Neutral LP | 2012-03-29 | 0.5 M | |
| HF | DAFNA Lifescience Select LP | 2012-03-29 | 213.5 M | |
| AUM Breakdown | Accounts | AUM ($M) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 4 | 645.2 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 4 | 645.2 |
| By Discretionary | ||
| Discretionary | 4 | 645.2 |
| Non-Discretionary | 0 | 0.0 |
| Total | 4 | 645.2 |
| By Non-United States Persons | ||
| Non-United States Persons | 204.2 | |
| United States Persons | 441.1 | |
| Total | 4 | 645.2 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Nathan Fischel | Executive Officer | 3 | 2 | |
| Fariba Ghodsian | Executive Officer | 1 | 1 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001389933] | |
| 3 | [0001389933] | |
| SC 13D | [0001389933] | |
| SC 13G | [0001389933] |
| Firm Profile (Form ADV) | |
|---|---|
| Discretionary AUM | $0.1B |
| Serves | Institutional |
| Fund Types | Hedge Fund |
| LEI | 254900W3EEPXDZYS3V12 |
| Form 3/4/5 Subject | 2011 - 2026 |
|---|---|
| Stereotaxis Inc | |
| DAFNA Capital Management LLC | |
| Ghodsian Fariba Fischel |
| Comparable Firms | State | AUM |
|---|---|---|
|
Goodlander Investment Management LLC
✚
|
TX | 660.5 M |
|
Polar Capital America Corporation
✚
|
FL | 656.1 M |
|
Rings Capital Management LLC
✚
|
IL | 653.0 M |
|
OCO Capital Partners LP
✚
|
NY | 651.8 M |
|
Guardian Point Capital LP
✚
|
VA | 646.4 M |
|
Karya Capital Management LLC
✚
|
NY | 643.5 M |
|
Jones Hill Capital LP
✚
|
NY | 642.4 M |
|
Stanley Capital Management LLC
✚
|
TX | 634.6 M |
|
Simcoe Capital Management LLC
✚
|
NY | 633.8 M |
|
G2 Investment Partners Management LLC
✚
|
NY | 630.2 M |